Try a new search

Format these results:

Searched for:

person:goldss01

in-biosketch:true

Total Results:

192


First International Consensus Report on Adnexal Masses: Management Recommendations

Glanc, Phyllis; Benacerraf, Beryl; Bourne, Tom; Brown, Douglas; Coleman, Beverly G; Crum, Christopher; Dodge, Jason; Levine, Deborah; Pavlik, Edward; Timmerman, Dirk; Ueland, Frederick R; Wolfman, Wendy; Goldstein, Steven R
The First International Consensus Conference on Adnexal Masses was convened to thoroughly examine the state of the science and to formulate recommendations for clinical assessment and management. The panel included representatives of societies in the fields of gynecology, gynecologic oncology, radiology, and pathology and clinicians from Europe, Canada, and the United States. In the United States, there are approximately 9.1 surgeries per malignancy compared to the European International Ovarian Tumor Analysis center trials, with only 2.3 (oncology centers) and 5.9 (other centers) reported surgeries per malignancy, suggesting that there is room to improve our preoperative assessments. The American College of Obstetricians and Gynecologists Practice Bulletin on "Management of Adnexal Masses," reaffirmed in 2015 (Obstet Gynecol 2007; 110:201-214), still states, "With the exception of simple cysts on a transvaginal ultrasound finding, most pelvic masses in postmenopausal women will require surgical intervention." The panel concluded that patients would benefit not only from a more conservative approach to many benign adnexal masses but also from optimization of physician referral patterns to a gynecologic oncologist in cases of suspected ovarian malignancies. A number of next-step options were offered to aid in management of cases with sonographically indeterminate adnexal masses. This process would provide an opportunity to improve risk stratification for indeterminate masses via the provision of alternatives, including but not limited to evidence-based risk-assessment algorithms and referral to an "expert sonologist" or to a gynecologic oncologist. The panel believed that these efforts to improve clinical management and preoperative triage patterns would ultimately improve patient care.
PMID: 28266033
ISSN: 1550-9613
CID: 2477012

Modern evaluation of the endometrium

Goldstein, Steven R
Abnormal uterine bleeding in women older than age 35 years, and certainly in menopausal patients, mandates evaluation, mainly to exclude cancer and hyperplasia, but also to better diagnose the source of the bleeding to appropriately manage the patient. In the past, dilation and curettage was the mainstay of diagnosis. This gave way to in-office suction pump-generated biopsies. Most recently, disposable biopsy instruments with their own internal piston to generate suction have become the standard of care. Rarely has such a technique received such widespread acceptance with such limited validation. Transvaginal ultrasonography, when technically feasible, is a noninvasive way to image the endometrial cavity. Saline-infusion sonohysterography is a subset of transvaginal ultrasonography reserved for patients in whom an adequate endometrial echo is not seen or when an endometrial echo is seen but not sufficiently thin. Appropriate understanding and use of transvaginal ultrasonography and addition of sonohysterography when necessary can allow a clinical algorithm that can triage patients with abnormal uterine bleeding to 1) no anatomic pathology best treated expectantly; 2) a global endometrial process, in which case random blind endometrial sampling is appropriate; or 3) a focal endometrial abnormality in which case endometrial sampling should be done with the visualization offered by hysteroscopy. Finally, the incidence of thick endometrial echo found incidentally in postmenopausal women with no bleeding is extremely high (10-17%) and should not trigger invasive endometrial sampling automatically
PMID: 20567184
ISSN: 1873-233x
CID: 110087

The conundrum of asymptomatic adnexal masses: a clinician's opinion [Editorial]

Goldstein, Steven R
PMID: 27017323
ISSN: 1097-6868
CID: 2058542

Sarcopenic obesity: a double whammy [Comment]

Goldstein, Steven R
PMID: 35674645
ISSN: 1530-0374
CID: 5283172

Proving microcystic ultrasound appearance of borderline ovarian tumors by three-dimensional 'silhouette' rendering

Timor-Tritsch, I E; Monteagudo, A; Popiolek, D A; Duncan, K M; Goldstein, S R
PMID: 35195307
ISSN: 1469-0705
CID: 5172182

Skin, hair and beyond: the impact of menopause

Zouboulis, C C; Blume-Peytavi, U; Kosmadaki, M; Roó, E; Vexiau-Robert, D; Kerob, D; Goldstein, S R
The skin is an endocrine organ and a major target of hormones such as estrogens, androgens and cortisol. Besides vasomotor symptoms (VMS), skin and hair symptoms often receive less attention than other menopausal symptoms despite having a significant negative effect on quality of life. Skin and mucosal menopausal symptoms include dryness and pruritus, thinning and atrophy, wrinkles and sagging, poor wound healing and reduced vascularity, whereas skin premalignant and malignant lesions and skin aging signs are almost exclusively caused by environmental factors, especially solar radiation. Hair menopausal symptoms include reduced hair growth and density on the scalp (diffuse effluvium due to follicular rarefication and/or androgenetic alopecia of female pattern), altered hair quality and structure, and increased unwanted hair growth on facial areas. Hormone replacement therapy (HRT) is not indicated for skin and hair symptoms alone due to the risk-benefit balance, but wider potential benefits of HRT (beyond estrogen's effect on VMS, bone, breast, heart and blood vessels) to include skin, hair and mucosal benefits should be discussed with women so that they will be able to make the best possible informed decisions on how to prevent or manage their menopausal symptoms.
PMID: 35377827
ISSN: 1473-0804
CID: 5219562

Uterine incision closure: Is it the culprit in the cesarean scar niche and related complications?

Antoine, Clarel; Goldstein, Steven R; Timor-Tritsch, Ilan E
ORIGINAL:0015565
ISSN: 1044-307x
CID: 5221202

Gynecologic Teleultrasound and COVID-19: Is There a Connection?

Timor-Tritsch, Ilan E; Goldstein, Steven R
PMID: 35312092
ISSN: 1550-9613
CID: 5190992

Bone health 2022: an update [Editorial]

de Villiers, T J; Goldstein, S R
PMID: 35041568
ISSN: 1473-0804
CID: 5131492

Ability to successfully image the endometrial echo on transvaginal ultrasound in asymptomatic postmenopausal women

Goldstein, S R; Khafaga, A
OBJECTIVES/OBJECTIVE:Women who experience postmenopausal bleeding (PMB) are considered to have endometrial cancer (EC) until proven otherwise. Initially, dilatation and curettage (D&C) was the gold standard of diagnosis. This was largely replaced by blind endometrial (EM) biopsy. However, recently, the relatively high false negative rate of such blind sampling in women with EC has become understood. Concomitantly, numerous studies indicate that an EM echo of ≤ 4 mm on transvaginal ultrasound (TV U/S) is a reliable enough test to exclude EC such that biopsy is not needed in initial cases of PMB. However, not all PM women will have anatomy that lends itself to a meaningful determination of EM thickness. This study was undertaken to evaluate the frequency of, and reasons for, an inability to adequately visualize an EM echo. METHODS:472 consecutive asymptomatic PM women had TV U/S as part of routine gynecologic care. Their charts and TV U/S were reviewed, and, if adequate, EM thickness was recorded. If EM thickness was not adequately visualized the reason, as judged by the examiner, for inadequacy was recorded. Other demographics included years since menopause, body mass index (BMI), and current use of hormone therapy. RESULTS:Of the 472 women, 292 (61.9%) had an EM echo that was well visualized and reliably measured (mean 3.0 mm, range 1.0 -28.0). Thus, in 180 PM women (38.1%), a distinct measurable EM echo was unable to be adequately visualized. The reasons were: fibroids (n=95, or 20.1% of overall cohort), adenomyosis (n=35, or 7.4% of overall cohort), axial uterus (n=50, or 10.6% of cohort). Mean years since menopause was 14.0 in those visualized (range 1-50), and 14.1 in non-visualized (range 1-40) (N.S.). Mean BMI was 23.9 in those visualized (range 16-41) and 25.4 (range 18-40) in those non-visualized (p=.015). CONCLUSIONS:TV U/S has become an accepted first step in the evaluation of PMB. However, in this cohort 39.8% of women had anatomic reasons for non-visualization of a reliable EM measurement including fibroids, adenomyosis, and axial uterus. There was no significant difference between groups based on years since menopause or current use of hormone therapy, but the mean BMI of the non-visualized group was significantly higher than those visualized. Clinicians should be cognizant of these potential limitations of TV U/S in the initial evaluation of women with PMB. This article is protected by copyright. All rights reserved.
PMID: 33998081
ISSN: 1469-0705
CID: 4895262